HilleVax, Inc. - Common Stock (HLVX)

HLVX stock results show that HilleVax missed analyst estimates for earnings per share the second quarter of 2024.

HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023.

U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by midday trading in New York. This comes after both indices reached fresh record highs last Friday.

Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.

HilleVax stock is down on Monday after HLVX investors learned of a failed Phase 2b clinical trial of its norovirus vaccine for infants.

Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroenteritis in infants. The study showed 5% efficacy and no significant clinical benefits. Development in infants will be discontinued.

HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024.

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.

HilleVax Inc (NASDAQ: HLVX) shares are trading lower by 8.5% to $13.20 Wednesday morning after the company announced pricing of its previously-announced public offering of comm

U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Gainers

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.